The design of novel cyclin dependent kinase inhibitors Simak Ali Division of Cancer, Department of Surgery & Cancer, Imperial College London Breast Cancer Statistics Each year in the UK > 44,000 women are diagnosed with breast cancer i.e. > 100 a day In the last 10 years, breast cancer rates in the UK have increased by 12% 8 in 10 breast cancers are diagnosed in women aged 50 and over 1 in 8 life time risk of developing breast cancer Commonest cancer in UK & Europe (even though it affects ~ only 1 gender) in 2006 outranked lung caner (which affects both sexes) for the 1st time Breast Cancer Treatment Based on Molecular Sub-Type BREAST CANCER 80% ER -ve Basal-like ErbB2 +ve Herceptin Metaplastic / Medullary / Mucinous / Others EGFR overexpression c-kit aß-crystallin BRCA1 deficiency Gefitinib, erlotinib Imatinib/Gleevec MEK inhibitors DNA damage Lapatinib PI3K inhibitors PARP inhibitors CI-1033 Possible novel treatment options for Basal-like Breast cancer ER +ve Normal-like Luminal B/C Luminal A Hormone Therapy Resistance to Hormone Therapy in Breast Cancer 80% breast tumours are ER +ve endocrine therapy (SERMs such as tamoxifen, faslodex, raloxifene; aromatase inhibitors) Highly effective, but: Intrinsic resistance (~65% cancers sensitive to Tamoxifen) Acquired resistance (sequencing with another SERM or AI) Determine mechanisms of endocrine resistance Identify new markers of increased risk or therapy failure New Therapeutic Strategies for the treatment of endocrine resistant breast cancer Estrogen Receptor Phosphorylation P Ser118 ER Transcription DNA (AF-1) Binding Hormone Binding (AF-2) Serine 118 Phosphorylation and Endocrine Resistance Immunodetection in breast tumours pre- and post-tamoxifen (relapse) treatment: P-Ser118 levels increased post-tamoxifen treatment (z = -2.357; p = 0.02) No significant increase in ER (z = -0.815; p = 0.42) P Ser118 ER Transcription DNA (AF-1) Binding Hormone Binding (AF-2) Ser118 is phosphorylated by TFIIH associated CDK7 +CDK7 350 350 Reporter Gene Activity (%) Reporter Gene Activity (%) 400 300 250 200 150 100 50 0 300 250 200 150 100 50 0 No Ligand +CDK7 Chen et al 2000 Mol Cell -14 -12 -10 -8 -6 Estrogen Concentration (M) Ser118 is phosphorylated by TFIIH associated CDK7 Chen et al 2000 Mol Cell CDK7 Function Cyclin B P Cdk1 Cdk7 (cdc2) Cyclin D P Cyclin A P Cell Cycle Cdk1 Cdk 4/6 Cyclin E (cdc2) P Cyclin A P TFIIH Cdk2 Cdk8 Cdk9 Cdk2 P P P P P P P P Cdk7 (Y1-S2-P3-T4-S5-P6-S7)52 PolII Development of Selective CDK7 Inhibitors A roscovitine B DGsolv -19.5 (kcal/mol) -14.5 (1) DGsolv (kcal/mol) -22.4 -16.7 C -21.4 -17.1 D E Development of Selective CDK7 Inhibitors 184 Compounds designed. 68 compounds synthesised and screened for inhibition of CDK7, CDK2, CDK5, CDK9. Primary screen: compounds at 100 nM IC50 determined (to 1 µM) for all compounds demonstrating >20% inhibition of CDK7 at 100 nM. 58 compounds inhibited CDK7 with IC50 <1000 nM 20 of these inhibited CDK7 with IC50 <100 nM. For these, IC50 determined for CDK2, CDK5, CDK9, if <1000 nM. BS-194 BS-181 BS-181 is a highly selective CDK7 inhibitor Kinase µmol/L CDK1 CDK2 CDK4 CDK5 CDK6 CDK7 CDK9 Roscovitine IC50 (µmol/L) SD 1.8 0.3 0.1 0.02 15.3 6.6 0.24 0.1 28 4.9 0.51 0.1 1.2 0.8 BS-181 IC50 (µmol/L) 8.1 0.88 33.0 3.0 47.0 0.021 4.2 Kinase µmol/L CDK2/Cyclin A CK1 DYRK1A SD 0.6 0.08 1.5 0.5 4.0 0.002 0.5 BS-181 IC50 (µmol/L) 0.75 7.4 2.3 Ali et al 2009 Cancer Research Protein Kinase MKK1 ERK1 ERK2 JNK1 JNK2 JNK3 p38 MAPK P38ß MAPK p38g MAPK p38s MAPK ERK8 RSK1 RSK2 PDK1 PKBa PKBb SGK1 S6K1 PKA ROCK 2 PRK2 PKCa PKC zeta PKD1 MSK1 MNK1 MNK2 MAPKAP-K2 MAPKAP-K3 PRAK CAMKKa CAMKKb CAMK1 SmMLCK PHK % Activity Remaining 96 108 86 100 90 128 95 115 108 96 32 67 55 80 82 81 42 95 110 76 90 98 114 53 65 105 105 88 119 115 57 67 48 35 49 Standard Deviation 7 10 10 6 8 9 1 2 1 2 1 9 2 8 14 8 10 10 13 0 9 2 7 5 10 7 11 7 9 2 5 0 8 4 12 % Activity Protein Kinase Remaining CHK1 80 CHK2 36 GSK3b 112 CDK2-Cyclin A 9 PLK1 100 PLK1 (Okadaic Acid) 108 AURORA B 95 AURORA C 98 AMPK 122 MARK3 104 BRSK2 98 MELK 63 CK1 29 CK2 108 DYRK1A 17 DYRK2 94 DYRK3 87 NEK2a 92 NEK6 85 NEK7 97 IKKb 96 PIM1 88 PIM2 102 PIM3 78 SRPK1 44 MST2 112 EFK2 119 HIPK2 88 HIPK3 90 PAK4 75 PAK5 80 PAK6 95 Src 88 Lck 95 CSK 89 Standard Deviation 4 2 8 1 13 13 7 5 8 0 6 0 6 8 1 7 1 9 2 9 1 6 3 10 2 8 13 1 8 8 8 9 8 9 9 BS-181 is a highly selective CDK7 inhibitor Table 2. In vitro growth inhibitory activity of BS-181 Breast Cell line MCF-7 MDA-MB-231 T47D ZR-75-1 BT474 BT20 Colorectal COLO-205 Lung A549 NCI-460 Osteosarcoma U2OS SaSO2 Prostate PC3 LNCaP Liver HepG2 Roscovitine BS-181 IC50 (µM) IC50 (µM) 13 18 25 33.5 30.5 32.5 8 17 9.5 10.5 13.9 10.8 8.4 12.3 20 15 16.5 25.5 30.5 19 11.5 37 21 14.5 20 23 32 24 50% inhibition: Roscovitine BS-181 Relative Tumour Volume Tumour Type MCF-7 4.5 4 3.5 3 2.5 2 1.5 1 0.5 0 * p<0.05 ** p<0.01 *** p<0001 Control (N=11) * * *** *** * *** *** *** *** Tumour Volume 0 2 4 6 8 Days Ali et al 2009 Cancer Research P-Ser2 P-Ser5 7.5 µmol/L >50 µmol/L 14.5 µmol/L 9.0 µmol/L 10 12 14 BS-181 10mg/kg/day (N=10) BS-181 20mg/kg/day (N=13) 80 * 60 40 * 20 0 DMSO 1µM 10µM 25µM BS-181 Concentration 50µM Ali et al 2009 Cancer Research MCF-7 100 80 60 40 * 20 * 0 DMSO 1µM 10µM 25µM BS-181 Concentration 50µM p53 ß-actin HCT116 p53+/+ HCT116 p53-/- 100 Percentage of apoptosis (n=3, +/- SEM) Percentage of apoptosis (n=3, +/-SEM) BS-181 promotes cell cycle block and p53-dependent apoptosis Summary Initial work identified Cdk7 as a protein kinase that regulates ER activity in breast cancer CADD using reported crystal structures and inhibitors allowed the identification of potential scaffolds for drug design towards selective Cdk7 inhibitors BS-181 identified as a highly selective Cdk7 inhibitor with anti-tumour activity in vivo However, BS-181 has poor ADMET/PK properties, which make its development as a cancer drug difficult BS-194, a potent CDK inhibitor Kinase µmol/L CDK1 CDK2 CDK4 CDK5 CDK6 CDK7 CDK9 BS-181 Roscovitine IC50 SD 1.8 0.3 0.1 0.02 15.3 6.6 0.24 0.1 28 4.9 0.51 0.1 1.2 0.8 BS-194 IC50 0.033 0.003 20.0 0.03 35.5 0.25 0.09 SD 0.01 0.001 1.3 0.006 1.3 0.004 0.04 100 NCI 60 Cancer Cell Lines: Mean GI50 = 2.81E-07 mol/L 80 BS-194 Percentage Growth 60 40 20 0 -20 -40 -60 -80 -100 -9 -8 -7 -6 -5 Log10 of Sample Concentration (Molar) Heathcote et al 2010 J Med Chem -4 BS-194, an orally bioavailable CDK inhibitor Relative tumor volume 6 HCT116 Xenograft 5 Vehicle BS194- 50mg/kg BS194- 25mg/kg 4 3 ** p<0.001 * p<0.01 2 * ** ** 1 0 1 4 * ** ** 7 11 ** 14 Days BS-194 Heathcote et al 2010 J Med Chem BS-194 crystallisation with Cdk2 Heathcote et al 2010 J Med Chem BS-181 and BS-194 as lead compounds for further development BS-181 BS-194 • CDK7 selective compound (IC50 18 nM • CDK2/pan inhibitor (IC50 2.4 nM (CDK2), IC50 25 (CDK7), IC50 880 nM (CDK2)) nM (CDK1), IC50 30 nM (CDK5)) • modest activity in cells (MCF-7): • good activity in cells (MCF-7): GI50 (21 M ), TGI (32 M), LC50 (48 M) GI50 (0.06 M ), TGI (0.1 M), LC50 (>100 M) • low bioavailability (PO: 2%, IP: 37%) • high bioavailability (PO: 88%, IP: 73%) and poor cell permeability (0.8 x 106 cm/sec) and high cell permeability (9.7 x 106 cm/sec) and metabolically stable (97% parent after 24h) Merge properties BS-181 and BS-194 as lead compounds for further development IC50 (nmol/L) CDK7 CDK2 CDK1 CDK5 CDK9 CDK4 CDK6 GI50 (nmol/L) MCF-7 GI50 HCT116 GI50 Oral Bioavailability (R)-Roscovitine BS-181 BS-194 ICEC0574 ICEC0768 ICEC0829 ICEC0510R ICEC0942 510 100 2100 160 950 13,500 23,500 21 880 8,100 3,000 4,200 33,000 47,000 250 3 33 30 90 20,000 35,500 27 1,290 4,000 7,900 55 19,410 51,000 76 1,620 2,200 4,300 200 15,100 26,000 20 1,100 1,400 8,340 260 1,000 ND 31 1,800 3,200 8,200 523 21,000 20,000 40 580 1,521 9,000 1,100 42,000 32,100 13,000 20,000 300 4,100 12,720 2,800 6,190 1,500 5,070 5,600 9,180 960 1,130 2% 88% 40% 30% 60% Summary Initial work identified Cdk7 as a protein kinase that regulates ER activity in breast cancer CADD using reported crystal structures and inhibitors allowed the identification of potential scaffolds for drug design towards selective Cdk7 inhibitors Lead compounds identified through in vitro assays and confirmed using biomarker and in vivo evaluation Reiterative design using CADD and chemistry at Imperial has now been used to identify further compounds with improved drug-like properties whilst maintaining target selectivity Acknowledgements Surgery & Cancer ESTROGEN SIGNALLING Dongsheng CHEN Manikandan PERIYASAMY Ross THOMAS Laki BULUWELA CDK INHIBITORS Sean DELANEY Dean HEATHCOTE Hetal PATEL Zahida ZAHOOR ADMET/PK Richard STARKEY Maciej KALISZCZAK Eric ABOAGYE Charles COOMBES Chemistry Basti KROLL Bodo SCHEIPER Alekasandra SIWICKA Robert PACE Alexander BONDKE Brian SLAFER Matt FUCHTER Tony BARRETT CADD, Emory Ashutosh JOGALEKAR Dennis LIOTTA Jim SNYDER IGBMC, Strasbourg Pierre CHAMBON Jean-Marc EGLY Molecular Biosciences Pascale HAZEL Paul FREEMONT Drug Discovery Centre Cathy TRALAU-STEWART Albert JAXA-CHAMIEC MD Anderson Tim MADDEN Garth POWIS Mount Sinai Stephane LAROCHELLE Robert FISHER